Search
World-first research from The Kids Research Institute Australia and Curtin University predicts climate change could trigger more than 100 million additional malaria cases and 500,000 additional deaths in Africa by 2050, including substantial impacts on children.
Research to eliminate one of the world’s deadliest diseases – malaria – will be accelerated thanks to a USD $4.7 million grant from the Gates Foundation for scientists at The Kids Research Institute Australia and The University of Western Australia (UWA).
The Malaria Atlas Project (MAP) – which houses the world’s largest malaria database and is at the forefront of efforts to track and tackle the disease – has been awarded more than $16 million by the Bill & Melinda Gates Foundation.
Disruptions of malaria case management caused by the COVID-19 pandemic likely contributed to an extra 76,000 malaria deaths in sub-Saharan Africa, according to analysis by The Kids Research Institute Australia and Curtin University.
A world-leading research team built to tackle malaria has relocated from Oxford University to Western Australia to take advantage of the state’s growing big data talent pool.
Namibia, a low malaria transmission country targeting elimination, has made substantial progress in reducing malaria burden through improved case management, widespread indoor residual spraying and distribution of insecticidal nets. The country's diverse landscape includes regions with varying population densities and geographical niches, with the north of the country prone to periodic outbreaks.
Climatic conditions are a key determinant of malaria transmission intensity, through their impacts on both the parasite and its mosquito vectors. Mathematical models relating climatic conditions to malaria transmission can be used to develop spatial maps of climatic suitability for malaria. These maps underpin efforts to quantify the distribution and burden of malaria in humans, enabling improved monitoring and control.
New malaria vaccine development builds on groundbreaking recommendations and roll-out of two approved pre-erythrocytic vaccines (PEVs); RTS,S/AS01 and R21/Matrix-M. Whilst these vaccines are effective in reducing childhood malaria within yearly routine immunization programs or seasonal vaccination, there is little evidence on how different PEV efficacies, durations of protection, and spacing between doses influence the potential to avert uncomplicated and severe childhood malaria.
The clinical development of novel vaccines, injectable therapeutics, and oral chemoprevention drugs has the potential to deliver significant advancements in the prevention of Plasmodium falciparum malaria. These innovations could support regions in accelerating malaria control, transforming existing intervention packages by supplementing interventions with imperfect effectiveness or offering an entirely new tool.
Melissa Penny PhD, PD, BSc (Hons) Professor Fiona Stanley Chair in Child Health Research melissa.penny@thekids.org.au Professor Fiona Stanley Chair